The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Big data on efficacy and toxicity levels for ibrutinib in CLL
George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, of Cambridge University, Cambridge, UK, discusses the implications of ibrutinib in chronic lymphocytic leukemia (CLL) patients and what long term data are showing. Dr Follows expresses his interest in seeing long term data on ibrutinib and how data is starting to take shape on venetoclax and other new drugs in CLL. In the UK, there has recently been a big data set published displaying a real world use for ibrutinib. Complex carrier type is evolving towards perhaps identifying those patients that are more likely to do less well, as the 17p deleted patients with longer follow ups seem to be less likely to stay on the drug. There haven’t been any longer term toxicities, or anything unexpected. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
